Comparing [18F]-PSMA-1007, [18F]-choline positron emission tomography, computerized tomography and bone scintigraphy...

Area of Science:

• Nuclear Medicine
• Radiopharmacology
• Oncology

Background:

• Prostate cancer (PC) is a major health concern, with biochemical recurrence (BRPC) common after treatment.
• [18F]-PSMA PET shows promise for detecting recurrence, but prospective comparative data are limited.
• Conventional methods like CT and bone scintigraphy have limitations in identifying recurrent prostate cancer.

Purpose of the Study:

• To prospectively evaluate the diagnostic performance of [18F] PSMA 1007 PET/CT in patients with biochemical recurrence of prostate cancer (BRPC).
• To compare the detection rates of [18F] PSMA 1007 PET/CT with conventional imaging modalities (CT, bone scintigraphy, [18F] choline PET).

Main Methods:

• Prospective observational study involving concordance analysis of imaging methods.
• Seventy-seven patients with BRPC following initial treatment were included.
• Comparison of imaging results from CT, bone scintigraphy, [18F] choline PET, and [18F] PSMA 1007 PET/CT.

Main Results:

• [18F] PSMA 1007 PET/CT detected recurrence in 84% of patients, significantly higher than CT (6%), bone scintigraphy (12%), and [18F] choline PET (35%).
• Detection rates of [18F] PSMA 1007 PET/CT correlated positively with prostate-specific antigen (PSA) levels.
• 100% detection was achieved with PSA levels ≥ 2 ng/mL.

Conclusions:

• [18F] PSMA 1007 PET/CT is a highly effective imaging tool for localizing recurrent prostate cancer in patients with BRPC.
• This advanced PET tracer offers superior diagnostic accuracy compared to conventional imaging for restaging prostate cancer.
• [18F] PSMA 1007 PET/CT enables more precise patient management by improving the detection of recurrent disease.